RESUMEN
OBJECTIVE: This study aimed to evaluate the benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease. METHODS: Sixty-six patients with Ménière's disease were randomly divided into three groups: betahistine, Tetrax and control groups. Patients' Dizziness Handicap Index and Tetrax fall index scores were obtained before and after treatment. RESULTS: Patients in the betahistine and Tetrax groups showed significant improvements in Dizziness Handicap Index and fall index scores after treatment versus before treatment (p < 0.05). The improvements in the Tetrax group were significantly greater than those in the betahistine group (p < 0.05). CONCLUSIONS: Betahistine and vestibular rehabilitation (Tetrax biofeedback) improve the quality of life and reduce the risk of falling in patients with Ménière's disease. Vestibular rehabilitation (Tetrax biofeedback) is an effective management method for Ménière's disease.
Asunto(s)
Accidentes por Caídas/prevención & control , Betahistina/uso terapéutico , Biorretroalimentación Psicológica/métodos , Agonistas de los Receptores Histamínicos/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Adulto , Anciano , Estudios de Casos y Controles , Terapia Combinada , Mareo/etiología , Femenino , Humanos , Masculino , Enfermedad de Meniere/rehabilitación , Persona de Mediana Edad , Calidad de Vida , Rehabilitación/métodos , Rehabilitación/estadística & datos numéricos , Medición de Riesgo , Resultado del Tratamiento , Vestíbulo del Laberinto/efectos de los fármacosRESUMEN
Meniere's disease (MD) represents a clinical syndrome characterized by episodes of spontaneous vertigo, associated with fluctuating, low to medium frequencies sensorineural hearing loss (SNHL), tinnitus, and aural fullness affecting one or both ears. To date, the cause of MD remains substantially unknown, despite increasing evidence suggesting that oxidative stress and neuroinflammation may be central to the development of endolymphatic hydrops and consequent otholitic degeneration and displacement in the reuniting duct, thus originating the otolithic crisis from vestibular otolithic organs utricle or saccule. As a starting point to withstand pathological consequences, cellular pathways conferring protection against oxidative stress, such as vitagenes, are also induced, but at a level not sufficient to prevent full neuroprotection, which can be reinforced by exogenous nutritional approaches. One emerging strategy is supplementation with mushrooms. Mushroom preparations, used in traditional medicine for thousands of years, are endowed with various biological actions, including antioxidant, immunostimulatory, hepatoprotective, anticancer, as well as antiviral effects. For example, therapeutic polysaccharopeptides obtained from Coriolus versicolor are commercially well established. In this study, we examined the hypothesis that neurotoxic insult represents a critical primary mediator operating in MD pathogenesis, reflected by quantitative increases of markers of oxidative stress and cellular stress response in the peripheral blood of MD patients. We evaluated systemic oxidative stress and cellular stress response in MD patients in the absence and in the presence of treatment with a biomass preparation from Coriolus. Systemic oxidative stress was estimated by measuring, in plasma, protein carbonyls, hydroxynonenals (HNE), and ultraweak luminescence, as well as by lipidomics analysis of active biolipids, such as lipoxin A4 and F2-isoprostanes, whereas in lymphocytes we determined heat shock proteins 70 (Hsp72), heme oxygenase-1 (HO-1), thioredoxin (Trx), and γ-GC liase to evaluate the systemic cellular stress response. Increased levels of carbonyls, HNE, luminescence, and F2-isoprostanes were found in MD patients with respect to the MD plus Coriolus-treated group. This was paralleled by a significant (p < 0.01) induction, after Coriolus treatment, of vitagenes such as HO-1, Hsp70, Trx, sirtuin-1, and γ-GC liase in lymphocyte and by a significant (p < 0.05) increase in the plasma ratio-reduced glutathione (GSH) vs. oxidized glutathione (GSSG). In conclusion, patients affected by MD are under conditions of systemic oxidative stress, and the induction of vitagenes after mushroom supplementation indicates a maintained response to counteract intracellular pro-oxidant status. The present study also highlights the importance of investigating MD as a convenient model of cochlear neurodegenerative disease. Thus, searching innovative and more potent inducers of the vitagene system can allow the development of pharmacological strategies capable of enhancing the intrinsic reserve of vulnerable neurons, such as ganglion cells to maximize antidegenerative stress responses and thus providing neuroprotection.
Asunto(s)
Agaricales/química , Polisacáridos Fúngicos/administración & dosificación , Enfermedad de Meniere , Enfermedades Neurodegenerativas , Fármacos Neuroprotectores/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Adulto , Femenino , Polisacáridos Fúngicos/química , Humanos , Masculino , Enfermedad de Meniere/sangre , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Enfermedades Neurodegenerativas/sangre , Enfermedades Neurodegenerativas/tratamiento farmacológico , Fármacos Neuroprotectores/químicaRESUMEN
PURPOSE: The uses of nimodipine for otolaryngic indications are reviewed, and recommendations for its use in clinical practice are provided. SUMMARY: Nimodipine is currently indicated for the improvement of neurologic outcomes in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). However, other oral and i.v. calcium channel blockers have not exhibited the same beneficial effects in patients with aSAH, leading clinicians to believe that nimodipine possesses unique neuroprotective effects in addition to its calcium channel-blocking and vasodilatory properties. Consequently, clinical investigations of nimodipine have been conducted for cochlear and facial nerve preservation after vestibular schwannoma (VS) surgery, symptomatic management of Ménière's disease and peripheral vertigo, and recovery of vocal cord paralysis after laryngeal nerve injury. Three prospective randomized studies have investigated nimodipine for hearing and/or nerve preservation in patients undergoing VS resection, the results of which have suggested a potential benefit of initiating nimodipine during the perioperative period. Several studies of Ménière's disease and/or peripheral vertigo have reported improved symptom control with nimodipine. For vocal fold paralysis associated with recurrent laryngeal nerve (RLN) injury, nimodipine may increase the recovery rate based on the results of 1 nonrandomized prospective study that used nimodipine in a protocolized manner. One small pilot study found that nimodipine improved facial nerve function after maxillofacial surgery. CONCLUSION: Due to its proposed vasoactive and neuroprotective effects, nimodipine may play a role in the treatment of a number of otolaryngic pathologies including VS, Ménière's disease, peripheral vertigo, RLN injury, and facial weakness after maxillofacial surgery. Small studies have shown improved symptom control and recovery after surgery. Since all of the aforementioned indications are still considered off label, clinicians and patients should collaboratively assess the risks and benefits before initiating treatment.
Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Nimodipina/uso terapéutico , Enfermedades Otorrinolaringológicas/tratamiento farmacológico , Humanos , Enfermedad de Meniere/tratamiento farmacológico , Vasodilatadores/uso terapéutico , Vértigo/tratamiento farmacológicoRESUMEN
AIM: The aim of this supplement registry was to evaluate the efficacy of the Pycnogenol® in improving cochlear flow and symptoms in a 6-month follow-up for patients with Meniere's disease (MD), tinnitus and cochlear hypoperfusion. METHODS: Main signs/symptoms were considered: Spontaneous vertigo, positional vertigo, hearing loss, tinnitus, pressure in the ear, unsteady gait, associated clinical problems, alterations in daily life. All subjects were managed with the best available management (BM); one group used the supplement Pycnogenol (150 mg/day). Cochlear flow and tinnitus were also evaluated. Out of 120 patients incuded in the registry, 55 used Pycnogenol and 52 (controls) were managed only with BM. RESULTS: There was a more significant improvement in all registry items at 3 and 6 months in the Pycnogenol group (P<0.05). The number of lost working days was lower in the Pycnogenol group. At 3 months, 45.4% of subjects using Pycnogenol were completely asymptomatic in comparison with 23.07% of controls. At 6 months 87.3% of the Pycnogenol subjects were asymptomatic compared with 34.6% of controls. Cochlear flow velocity was significantly better (higher flow, higher diastolic component) in the Pycnogenol group (P<0.05). The subjective tinnitus scale decreased in both groups (P<0.05); the decrease was more significant in Pycnogenol subjects (P<0.05) at 3 and 6 months. CONCLUSION: Symptoms of Meniere's disease, flow at cochlear level and tinnitus improved in Pycnogenol subjects in comparison with best management.
Asunto(s)
Cóclea/irrigación sanguínea , Flavonoides/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Acúfeno/tratamiento farmacológico , Adulto , Anciano , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Femenino , Humanos , Masculino , Enfermedad de Meniere/complicaciones , Enfermedad de Meniere/diagnóstico , Persona de Mediana Edad , Extractos Vegetales , Flujo Sanguíneo Regional/efectos de los fármacos , Sistema de Registros , Factores de Tiempo , Acúfeno/etiología , Resultado del TratamientoRESUMEN
Vertigo and dizziness are with a life-time prevalence of ~30% among the most common symptoms and are often associated with nystagmus or other oculomotor disorders. The prerequisite for a successful treatment is a precise diagnosis of the underlying disorder. In this overview, the current pharmacological treatment options for peripheral and central vestibular, cerebellar, and oculomotor disorders including nystagmus are described. There are basically seven groups of drugs that can be used (the "7 As"): antiemetics; anti-inflammatory, anti-Menière's, and antimigraine medications; antidepressants, anticonvulsants, and aminopyridines. In acute vestibular neuritis, recovery of the peripheral vestibular function can be improved by treatment with oral corticosteroids. In Menière's disease, a long-term high-dose treatment with betahistine-dihydrochloride (at least 48 mg three times daily) had a significant effect on the frequency of the attacks; the underlying mode of action is evidently an increase in inner-ear blood flow. The use of aminopyridines is a well-established therapeutic principle in the treatment of downbeat and upbeat nystagmus as well as episodic ataxia type 2 and cerebellar gait disorders. As was shown in animal experiments, these potassium channel blockers increase the activity and excitability and normalize irregular firing of cerebellar Purkinje cells. They evidently augment the inhibitory influence of these cells on vestibular and deep cerebellar nuclei. A few studies showed that baclofen improves periodic alternating nystagmus; gabapentin and memantine improve pendular and infantile nystagmus. However, many other eye-movement disorders such as ocular flutter, opsoclonus, central positioning, and see-saw nystagmus are still difficult to treat. Although substantial progress has been made, further state-of-the-art trials must still be performed on many vestibular and oculomotor disorders, namely Menière's disease, vestibular paroxysmia, vestibular migraine, and many forms of central eye-movement disorders.
Asunto(s)
Nistagmo Patológico/tratamiento farmacológico , Enfermedades Vestibulares/tratamiento farmacológico , Animales , Enfermedades Cerebelosas/tratamiento farmacológico , Mareo/tratamiento farmacológico , Humanos , Enfermedad de Meniere/tratamiento farmacológico , Oftalmoplejía/tratamiento farmacológico , Neuronitis Vestibular/tratamiento farmacológicoRESUMEN
Ménière's disease (MD) is a progressive disease of the inner ear characterized by recurring attacks of disabling vertigo, hearing loss and tinnitus. Patients who do not respond to vestibular sedatives or steroids may require an intratympanic application of aminoglycoside antibiotics, which destroys the vestibular function of the affected ear in order to avoid the debilitating vertigo attacks. Although effective, this procedure causes hearing loss in almost one third of the patients due to the aminoglycosides cochlear toxicity. Here we describe the synthesis of two pseudodisaccharides structurally related to neamime aiming to mimic the aminoglycosides pharmacophore core by replacing their toxic amine by azide and hydroxyl groups. Products 1 and 2 selectively promoted 'in vivo' damage to vestibular tissues without causing hearing loss or cochlear toxicity. Therefore, these pseudodisaccharides stand as promising lead compounds for the development of a safer and more effective therapeutic procedure to manage the symptoms of MD severe dizziness.
Asunto(s)
Azidas/química , Azidas/farmacología , Disacáridos/química , Disacáridos/farmacología , Framicetina/química , Vértigo/tratamiento farmacológico , Aminoglicósidos/química , Animales , Azidas/síntesis química , Técnicas de Química Sintética , Cóclea/citología , Cóclea/efectos de los fármacos , Disacáridos/síntesis química , Evaluación Preclínica de Medicamentos/métodos , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Cobayas , Células Ciliadas Auditivas/efectos de los fármacos , Humanos , Enfermedad de Meniere/tratamiento farmacológico , Microscopía Electrónica de Rastreo , Imitación Molecular , Estructura MolecularRESUMEN
A consolidated therapy for "idiopathic" acute disorders of the inner ear, including Meniere's Disease (MD), does not exist despite the long-lasting and widespread attempts: this lack is strictly linked to pathogenic uncertainties. According to the theoretical model that our group developed and tested over the years, a possible cause of labyrinthine damage could be identified in systemic hemodynamic changes followed by an abnormal peripheral vasoconstriction: the latter could be responsible for a more or less prolonged ischemia able to threaten a highly energy-requiring and complicated organ as the inner ear. A possible way to treat MD attacks - as well as other inner ear disorders that possibly share the same origin - according to our model should be addressed to modulate the peripheral circulation and to maintain the balance of ion exchange, acting both on systemic hemodynamics and on cell and organelle membranes. Despite the absence of such a proposal in the English literature, a reliable solution could derive from the supplementation of the intake of a nutritional principle as Omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) that seem to theoretically fulfil all the requirements necessary to achieve a homeostasis of the inner ear.
Asunto(s)
Ácidos Grasos Omega-3/uso terapéutico , Enfermedades del Laberinto/tratamiento farmacológico , Enfermedad de Meniere/tratamiento farmacológico , Hemodinámica/efectos de los fármacos , Homeostasis , Humanos , Enfermedades del Laberinto/etiología , Enfermedades del Laberinto/fisiopatología , Enfermedad de Meniere/etiología , Enfermedad de Meniere/fisiopatología , Modelos BiológicosRESUMEN
OBJECTIVE: To evaluate the clinical effectiveness and safety of Sanchi Tong Shu capsule in the treatment of common aural vertigo. METHOD: A multi-center randomized controlled trial was designed to study 206 vertigo patients who were randomly allocated into one of the two groups. One group was treated with Sanchi Tong Shu capsule for 14 days, another group was treated with betahistine mesilate tablets for 14 days. RESULT: The clinical effectiveness rates of the two groups were 84.86% and 90.92% respectively according to FAS analysis and 84.76%, 90.92% respectively according to PPS analysis. No statistic significance difference was found between the two groups (P > 0.05). After 14 days treatment, total DHI and all the subsection (including body, emotion and function) scores of the two groups were all decreased compared with treatment before (P < 0.01). Compared the difference value of the total DHI and subsection scores before and after treatment, the two groups have no difference (P > 0.05). The adverse effective rate of the two groups were 3.29% and 7.84% respectively and there was no statistic difference between the two groups (P > 0.05). CONCLUSION: Sanchi Tong Shu capsule is a safe and effective drug for the treatment of common aural vertigo.
Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Fitoterapia , Adolescente , Adulto , Betahistina/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto JovenRESUMEN
Despite an abundance of long-term pharmacological treatments for recurrent vertigo attacks due to Ménière's disease, there is no general agreement on the their efficacy. We present the results of a retrospective study based on a 10-year experience with two long-term medical protocols prescribed to patients affected by Ménière's disease (diagnosed according to the American Academy of Otolaryngology-Head and Neck Surgery Committee on Hearing and Equilibrium guidelines) who completed treatments in the period 1999-2009. A total of 113 medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period. Nimodipine, a 1,4-dihydropyridine that selectively blocks L-type voltage-sensitive calcium channels, has previously been tested as a monotherapy for recurrent vertigo of labyrinthine origin in a multinational, double-blind study with positive results. A moderate reduction of the impact of vertigo on quality of life (as assessed by the Dizziness Handicap Inventory) was obtained in patients after therapy with betahistine (p < 0.05), but a more significant effect was achieved in patients treated by combined therapy (p < 0.005). In the latter group, better control of vertigo was seen with a greater reduction of frequency of attacks (p < 0.005). Both protocols resulted in a significant improvement of static postural control, although a larger effect on body sway area in all tests was obtained by the fixed combination of drugs. In contrast, no beneficial effect on either tinnitus annoyance (as assessed by the Tinnitus Handicap Inventory) and hearing loss (pure-tone average at 0.5, 1, 2, 3 kHz frequencies of the affected ear) was recorded in patients treated with betahistine as monotherapy (p > 0.05), whereas the fixed combination of betahistine and nimodipine was associated with a significant reduction of tinnitus annoyance and improvement of hearing loss (p < 0.005). It was concluded that nimodipine represents not only a valid add-therapy for Ménière's disease, and that it may also exert a specific effect on inner ear disorders. Further studies to investigate this possibility are needed.
Asunto(s)
Betahistina/administración & dosificación , Nimodipina/administración & dosificación , Vasodilatadores/administración & dosificación , Adulto , Quimioterapia Combinada , Femenino , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Estudios Retrospectivos , Factores de TiempoRESUMEN
CONCLUSION: Betahistine dihydrochloride, a drug used widely in the systemic treatment of balance disorders such as Ménière's disease, was found to improve eustachian tube function when applied topically in the nasopharynx of rats. OBJECTIVES: The study tested the effect of betahistine, a histamine receptor agonist, on eustachian tube function and tested the involvement of H1 and H3 histamine receptors. METHODS: Eustachian tube function was measured in anaesthetized rats while middle ear pressure was increased and then monitored during induced swallowing. Betahistine and other drugs were applied topically in the nasopharynx, bulla and epipharynx, and administered intraperitoneally. RESULTS: Systemic application of betahistine hardly changed eustachian tube function, but topical application significantly improved it. The action of topical betahistine was unaffected by the HI receptor antagonist mepyramine and was mimicked by the H3 agonist, ciproxifan.
Asunto(s)
Betahistina/administración & dosificación , Trompa Auditiva/efectos de los fármacos , Agonistas de los Receptores Histamínicos/administración & dosificación , Administración Tópica , Animales , Barotrauma/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Otitis Media/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Receptores Histamínicos/metabolismoRESUMEN
BACKGROUND: The lifelong prevalence of rotatory vertigo is 30%. Despite this high figure, patients with vertigo generally receive either inappropriate or inadequate treatment. However, the majority of vestibular disorders have a benign cause, take a favorable natural course, and respond positively to therapy. OBJECTIVE: This review puts special emphasis on the medical rather than the physical, operative, or psychotherapeutic treatments available. METHODS: A selected review of recent reports and studies on the medical treatment of peripheral and central vestibular disorders. RESULTS/CONCLUSIONS: In vestibular neuritis, recovery of the peripheral vestibular function can be improved by oral corticosteroids; in Menière's disease, there is first evidence that high-dose, long-term administration of betahistine reduces attack frequency; carbamazepine or oxcarbamazepine is the treatment of first choice in vestibular paroxysmia, a disorder mainly caused by neurovascular cross-compression; the potassium channel blocker aminopyridine provides a new therapeutic principle for treatment of downbeat nystagmus, upbeat nystagmus, and episodic ataxia type 2.
Asunto(s)
Benzodiazepinas/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Enfermedades Vestibulares/tratamiento farmacológico , Neuronitis Vestibular/tratamiento farmacológico , Humanos , Preparaciones Farmacéuticas , Vértigo/etiologíaRESUMEN
Meniere's Disease is commonly diagnosed using Electrocochleography (ECOG). EVestG is a variant of ECOG utilizing one or more patient tilts as stimuli in place of the ECOG's repeated tonal clicks. The dynamic measures averaged 'background-onAA' (onAA=acceleration phase of tilt) and background-onBB (onBB=deceleration phase of tilt) of excitatory (ipsilateral tilt) vestibular responses are compared for a small group of age matched Controls (n=18) and Meniere's Disease patients (n=11). Preliminary data provides for an apparent clearer demarcation between Controls and Meniere's patients. Meniere's patients appear to show not only increased Sp/Ap ratios but also a decreased dynamic range of response as measured by the EVestG response measure averaged 'background-onBB'. Increased sample size is required to validate these findings.
Asunto(s)
Oído Interno/anatomía & histología , Enfermedad de Meniere/diagnóstico , Enfermedad de Meniere/tratamiento farmacológico , Estimulación Acústica , Algoritmos , Audiometría de Respuesta Evocada/métodos , Audiometría de Tonos Puros , Potenciales Microfónicos de la Cóclea , Diagnóstico por Computador , Potenciales Evocados Auditivos , Humanos , Enfermedad de Meniere/clasificación , Reproducibilidad de los Resultados , Procesamiento de Señales Asistido por ComputadorRESUMEN
UNLABELLED: Drug treatment is an important option for the treatment of peripheral vestibular diseases. AIM: To identify the drug component associated with optimal integrated balance therapy (IBT) for Ménières disease or other peripheral vestibular disorders. MATERIALS AND METHODS: Analysis of a series of patients with Ménières disease patients or patients with other peripheral vestibular disorders that received IBT involving either no medication or betahistine, cinnarizine, clonazepam, flunarizine or Ginkgo biloba during 120 days. RESULTS: In Ménières disease, significant differences were observed for all drug therapies (60 days) versus no medication; betahistine was significantly more effective than all other drugs at 60 and 120 days. For non-Ménières disorders, significant differences were observed among betahistine, cinnarizine, clonazepam and flunarizine and no medication after 60 days; all drug therapies were significantly more effective than no medication after 120 days; betahistine, cinnarizine or clonazepam were equally effective and betahistine was more effective than flunarizine and EGb 761. All treatment options were well tolerated. CONCLUSIONS: Drug therapies were more effective than no medication in the IBT for patients with Ménières disease or other peripheral vestibular disorders. Betahistine was the most effective medication for patients with Ménières disease and was as effective as cinnarizine and clonazepam for other peripheral vestibular disorders.
Asunto(s)
Agonistas de los Receptores Histamínicos/uso terapéutico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Enfermedad de Meniere/terapia , Enfermedades Vestibulares/terapia , Betahistina/uso terapéutico , Cinarizina/uso terapéutico , Clonazepam/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Femenino , Flunarizina/uso terapéutico , Ginkgo biloba , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Persona de Mediana Edad , Extractos Vegetales/uso terapéutico , Resultado del Tratamiento , Enfermedades Vestibulares/tratamiento farmacológicoRESUMEN
Classical Ménière's disease is rarely found in children and literature regarding it is scarce. In general, the frequency of Ménière's disease in children is only 0.4-7.0 per cent of that in adults. The progression pattern of Ménière's disease in children is not known well. Here, we report three cases of Ménière's disease in children less than 15 years old, treated over nine years. The three cases comprise 14- and 13-year-old boys and a nine-year-old girl. Two of the three patients initially complained only of recurrent bouts of vertigo, without any tinnitus, ear fullness or hearing impairment. In all three cases, the early pure tone audiograms showed only high tone frequency loss, regardless of subjective hearing loss, and the decrease in the hearing threshold was observed one to eight years after the dizziness attacks began. The hearing threshold was usually decreased to a level of mild or moderate hearing impairment. After diuretic treatment, vertigo was generally well controlled, and some cases showed improvement in hearing. Of the total number of patients with Ménière's disease who visited our department over nine years, 2.6 per cent (3/114) were children, and the overall incidence of Ménière's disease in children with vertigo was 2.0 per cent (3/147). In conclusion, Ménière's disease in children rarely develops and may have characteristics of high tone loss in initial audiograms.
Asunto(s)
Enfermedad de Meniere , Adolescente , Audiometría de Tonos Puros , Niño , Terapia Combinada , Femenino , Ginkgo biloba , Pérdida Auditiva/tratamiento farmacológico , Pérdida Auditiva/etiología , Humanos , Hidroclorotiazida/uso terapéutico , Masculino , Enfermedad de Meniere/diagnóstico , Enfermedad de Meniere/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéutico , Trimetazidina/uso terapéutico , Vasodilatadores/uso terapéuticoRESUMEN
PURPOSE: In this decision-tree analysis, the costs of otogenic vertigo treatment were investigated from the third-party payer's perspective. Either the combination preparation, with cinnarizine 20 mg and dimenhydrinate 40 mg as active substances, or betahistine (12 mg betahistinedimesilate) was administered. METHODS: A core model, based on clinical studies, was developed and a cost-effectiveness analysis was conducted. Both differences in effectiveness of the alternative treatments and adverse reactions and side effects were included. The number of cases, in which no more symptoms of dizziness were detected after 4 weeks of therapy, served as the effectiveness parameter. RESULTS: The effectiveness-adjusted costs amounted to 130.11 Euros for patients treated with the combination preparation and 629.28 Euros for treatment with betahistine. CONCLUSION: From the third-party payer's perspective, therapy of otogenic vertigo with the combination preparation is more cost-effective than a treatment with betahistine. From the patient's perspective, the higher effectiveness and the superior profile of side effects militate in favor of a therapy with the combination preparation.
Asunto(s)
Betahistina/economía , Cinarizina/economía , Dimenhidrinato/economía , Costos de los Medicamentos/estadística & datos numéricos , Agonistas de los Receptores Histamínicos/economía , Enfermedad de Meniere/economía , Adulto , Betahistina/efectos adversos , Betahistina/uso terapéutico , Cinarizina/efectos adversos , Cinarizina/uso terapéutico , Análisis Costo-Beneficio , Árboles de Decisión , Dimenhidrinato/efectos adversos , Dimenhidrinato/uso terapéutico , Combinación de Medicamentos , Medicina Basada en la Evidencia , Femenino , Agonistas de los Receptores Histamínicos/efectos adversos , Agonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Programas Nacionales de Salud/economíaAsunto(s)
Gentamicinas/administración & dosificación , Enfermedad de Meniere/tratamiento farmacológico , Trastornos Migrañosos/tratamiento farmacológico , Picrotoxina/administración & dosificación , Vértigo/tratamiento farmacológico , Neuronitis Vestibular/tratamiento farmacológico , Acetazolamida/administración & dosificación , Acetazolamida/efectos adversos , Adulto , Anciano , Betahistina/administración & dosificación , Betahistina/efectos adversos , Dexametasona/administración & dosificación , Dexametasona/efectos adversos , Oído Medio/efectos de los fármacos , Oído Medio/fisiopatología , Gentamicinas/efectos adversos , Humanos , Inyecciones , Enfermedad de Meniere/diagnóstico , Enfermedad de Meniere/fisiopatología , Persona de Mediana Edad , Trastornos Migrañosos/fisiopatología , Manipulaciones Musculoesqueléticas , Membrana Otolítica/fisiopatología , Modalidades de Fisioterapia , Picrotoxina/efectos adversos , Prednisona/administración & dosificación , Prednisona/efectos adversos , Autocuidado , Sulpirida/administración & dosificación , Sulpirida/efectos adversos , Vértigo/fisiopatología , Neuronitis Vestibular/fisiopatologíaRESUMEN
OBJECTIVE: To measure the frequency dynamics of the vestibular evoked myogenic potential in patients with endolymphatic hydrops. STUDY DESIGN: A prospective study. SETTING: A university hospital. SUBJECTS: The endolymphatic hydrops group consisted of 28 affected ears of patients with definite unilateral Ménière's disease and a control group of 36 ears of 20 healthy volunteers. INTERVENTIONS: Vestibular evoked myogenic potentials generated by tone bursts at 250, 500, 700, 1,000, 1,500, 2,000, and 4,000 Hz were measured in both groups. Vestibular evoked myogenic potentials were also measured after furosemide administration in six patients in the endolymphatic hydrops group. MAIN OUTCOME MEASURE: The frequency sensitivity of vestibular evoked myogenic potential, as evaluated by p13-n23 normalized amplitude. RESULTS: Peak amplitudes were noted at 500 Hz in the control group and at 1,000 Hz in the endolymphatic hydrops group. After furosemide loading, peak amplitude shifted to a lower frequency in four of six ears. CONCLUSION: The peak amplitude of vestibular evoked myogenic potentials in the endolymphatic hydrops group was at a higher frequency than in the control group. The frequency of the saccule (nu) should be proportional to radical(tau/sigma), where tau is the tension of membrane and sigma is its density. We advocate the hypothesis that the shift in frequency dynamics of vestibular evoked myogenic potential in patients with endolymphatic hydrops originates from the morphologic features of the saccule, analogous to an expanded balloon.
Asunto(s)
Hidropesía Endolinfática/diagnóstico , Potenciales Evocados Motores/fisiología , Enfermedad de Meniere/diagnóstico , Nervio Vestibular/fisiopatología , Estimulación Acústica , Adulto , Anciano , Hidropesía Endolinfática/tratamiento farmacológico , Hidropesía Endolinfática/fisiopatología , Potenciales Evocados Motores/efectos de los fármacos , Femenino , Furosemida/administración & dosificación , Humanos , Contracción Isométrica/efectos de los fármacos , Contracción Isométrica/fisiología , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Enfermedad de Meniere/fisiopatología , Persona de Mediana Edad , Estudios Prospectivos , Procesamiento de Señales Asistido por Computador , Espectrografía del Sonido , Nervio Vestibular/efectos de los fármacosRESUMEN
Treatment of Menière's disease is aimed at restoring a normal quality of life and preserving residual hearing, in view of the increasing frequency with which the contralateral ear is affected. Conventional medical treatment (diuretics + vasoactive drugs) leads to cure in a large percentage of patients (75-95%). In intractable cases, transtympanic (intratympanic) aminoglycoside therapy, associated with various techniques, is becoming widespread as an alternative to surgery. Progressive reduction of the dose introduced into the middle ear did not prevent the onset of anacusis in several patients; the variable, unpredictable permeability of the round window membrane, the object of fundamental studies in the past, explains this complication. The Author has used gentamicin transtympanically in Menierians since 1978, and has treated a total of 105 patients. He first prescribed transtympanic gentamicin therapy that did not follow, but was integrated with conventional medical treatment in 22 intractable Menierians, by instilling the minimum effective dose, to reduce the risk of hearing impairment. Preliminary results, related to stage of disease, may be summarised as follows: improvement in the quality of life, as evaluated by the American Academy of Ophthalmology & Otolaryngology Committee on Hearing and Equilibrium questionnaire (14 patients--63.63%--at point 1 and 8-36.36%--at point 2); disappearance of vertigo in 15 patients (68.18%); a minor vertigo attack in 3 and two minor attacks in 3 others not affecting quality of life; persistence of occasional unsteadiness in one patient. Hearing remained unchanged in 15 patients, improved slightly in 3 cases and worsened slightly in 2; decreased sensitivity to high tones was observed in 2 patients at the first insertion of gentamicin. According to the Author, employing integrated therapy and using the minimum effective dose of gentamicin, the risk of damage to the cochlear structures may be reduced, although not excluded, while restoring a good quality of life, even when repeat instillation is necessary.
Asunto(s)
Antibacterianos/uso terapéutico , Gentamicinas/uso terapéutico , Enfermedad de Meniere/tratamiento farmacológico , Administración Tópica , Adulto , Anciano , Antibacterianos/administración & dosificación , Relación Dosis-Respuesta a Droga , Hidropesía Endolinfática/complicaciones , Femenino , Gentamicinas/administración & dosificación , Humanos , Masculino , Enfermedad de Meniere/etiología , Persona de Mediana Edad , Calidad de VidaRESUMEN
In this paper possibility of employing vestibular evoked myogenic potentials (VEMPs) was evaluated to following efficacy of drug effect in patients with central and peripheral vestibular disorders of various aetiologies. Also influence of antihomotoxic remedies on sacculo-collic reflex function were followed. Treatment concerned 23 ills that is 20 women and 3 men in age from 20 to 68 years, average age being 46,82 years. The studied population included 8 patients were diagnosed to have Meniere's disease, 5 ills suffered from neuronitis vestibularis, 5 patients complained of vertigo of vertebrobasilar arterial insufficiency. 3 patients were diagnosed to have vertigo after head trauma, 1 patient suffered from benign paroxysmal positional vertigo and one's cause of disease was unknown. Patients with tumor of ponto-cerebellaris angle or VIII nerve were excluded. Registration of VEMPs was done in all patients treated before starting and after stopping therapy. After using of Cerebrum comp. improvement of vestibulo-spinal reflex function was affirmed in the form of shorted latencies and higher amplitudes of VEMPs in the most patients. Using sublingually of Vertigoheel distinct greater amplitudes were observed in significant numbers of patients after therapy. Administered of placebo did not essential influence on values of VEMPs parameters.